KR101695329B1 - 소아 급성 림프구성 백혈병의 치료방법 - Google Patents

소아 급성 림프구성 백혈병의 치료방법 Download PDF

Info

Publication number
KR101695329B1
KR101695329B1 KR1020117010642A KR20117010642A KR101695329B1 KR 101695329 B1 KR101695329 B1 KR 101695329B1 KR 1020117010642 A KR1020117010642 A KR 1020117010642A KR 20117010642 A KR20117010642 A KR 20117010642A KR 101695329 B1 KR101695329 B1 KR 101695329B1
Authority
KR
South Korea
Prior art keywords
pediatric
pharmaceutical composition
single chain
treatment
bispecific single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117010642A
Other languages
English (en)
Korean (ko)
Other versions
KR20110091669A (ko
Inventor
게르하르트 쭈크마이어
Original Assignee
암젠 리서치 (뮌헨) 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 리서치 (뮌헨) 게엠베하 filed Critical 암젠 리서치 (뮌헨) 게엠베하
Publication of KR20110091669A publication Critical patent/KR20110091669A/ko
Application granted granted Critical
Publication of KR101695329B1 publication Critical patent/KR101695329B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117010642A 2008-11-07 2009-11-06 소아 급성 림프구성 백혈병의 치료방법 Active KR101695329B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
US22126909P 2009-06-29 2009-06-29
US61/221,269 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (2)

Publication Number Publication Date
KR20110091669A KR20110091669A (ko) 2011-08-12
KR101695329B1 true KR101695329B1 (ko) 2017-01-23

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117010642A Active KR101695329B1 (ko) 2008-11-07 2009-11-06 소아 급성 림프구성 백혈병의 치료방법

Country Status (27)

Country Link
US (2) US20110262440A1 (https=)
EP (4) EP2344539B1 (https=)
JP (2) JP5798036B2 (https=)
KR (1) KR101695329B1 (https=)
CN (2) CN102209729B (https=)
AU (1) AU2009313039B2 (https=)
BR (1) BRPI0921341A2 (https=)
CA (1) CA2742242C (https=)
CY (3) CY1116160T1 (https=)
DK (3) DK2918604T3 (https=)
ES (3) ES2748126T3 (https=)
HK (1) HK1255590B (https=)
HR (3) HRP20150400T1 (https=)
HU (3) HUE046222T2 (https=)
IL (1) IL212651A (https=)
LT (2) LT3330293T (https=)
MX (1) MX2011002931A (https=)
NO (1) NO2918604T3 (https=)
NZ (1) NZ591312A (https=)
PL (3) PL2918604T3 (https=)
PT (3) PT3330293T (https=)
RS (3) RS59348B1 (https=)
RU (3) RU2536933C2 (https=)
SG (1) SG195549A1 (https=)
SI (3) SI2344539T1 (https=)
SM (3) SMT201900546T1 (https=)
WO (1) WO2010052013A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190111324A (ko) 2018-03-22 2019-10-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
EP2386062B1 (en) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2715679T3 (es) 2014-05-30 2019-06-05 Amgen Res Munich Gmbh Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B
US20170252364A1 (en) * 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
HK1250146A1 (zh) 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
RS66511B1 (sr) 2015-05-20 2025-03-31 Amgen Res Munich Gmbh Deplecija b ćelija kao dijagnostički marker
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
AU2016378573A1 (en) * 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
MX2019013142A (es) * 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12285494B2 (en) 2021-02-16 2025-04-29 Children's Health Care Methods for treating B-ALL by administering a pre-BCR complex antagonist
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250282864A1 (en) 2021-10-15 2025-09-11 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engagers
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193852A1 (en) * 1998-04-21 2006-08-31 Micromet Ag Novel CD19xCD3 specific polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
DK1976886T3 (en) 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PL2352763T5 (pl) * 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
CN102282128B (zh) * 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
MX2011012632A (es) * 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193852A1 (en) * 1998-04-21 2006-08-31 Micromet Ag Novel CD19xCD3 specific polypeptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood, Vol 80, Pages 2826-2834(1992.12.01.)*
SCIENCE, Vol 321, Pages 974-977(2008.08.15.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190111324A (ko) 2018-03-22 2019-10-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물

Also Published As

Publication number Publication date
DK2918604T3 (en) 2018-03-19
SI2344539T1 (sl) 2015-06-30
EP2918604B1 (en) 2017-12-20
JP2015232023A (ja) 2015-12-24
JP2012508163A (ja) 2012-04-05
ES2662929T3 (es) 2018-04-10
NZ591312A (en) 2012-09-28
CY1116160T1 (el) 2017-02-08
RU2018144313A3 (https=) 2020-06-15
CY1122428T1 (el) 2021-01-27
KR20110091669A (ko) 2011-08-12
ES2748126T3 (es) 2020-03-13
HRP20180426T1 (hr) 2018-04-20
RS56989B1 (sr) 2018-05-31
RU2536933C2 (ru) 2014-12-27
HRP20191715T1 (hr) 2019-12-13
CA2742242A1 (en) 2010-05-14
IL212651A0 (en) 2011-07-31
MX2011002931A (es) 2011-04-11
IL212651A (en) 2015-03-31
LT3330293T (lt) 2019-10-10
JP6130451B2 (ja) 2017-05-17
RU2677324C2 (ru) 2019-01-16
HK1215258A1 (en) 2016-08-19
CY1120022T1 (el) 2018-12-12
SMT201900546T1 (it) 2019-11-13
PT2344539E (pt) 2015-04-01
PL3330293T3 (pl) 2020-02-28
CA2742242C (en) 2023-01-10
HUE046222T2 (hu) 2020-02-28
RU2018144313A (ru) 2020-06-15
DK2344539T3 (en) 2015-05-04
EP3594237A1 (en) 2020-01-15
HK1255590B (en) 2020-07-10
BRPI0921341A2 (pt) 2016-04-26
PT3330293T (pt) 2019-10-18
LT2918604T (lt) 2018-03-26
SMT201800149T1 (it) 2018-05-02
HUE025452T2 (en) 2016-05-30
RS53980B1 (sr) 2015-10-30
AU2009313039A1 (en) 2010-05-14
NO2918604T3 (https=) 2018-05-19
US20230235053A1 (en) 2023-07-27
EP3330293B1 (en) 2019-07-24
PL2344539T3 (pl) 2015-07-31
SI2918604T1 (en) 2018-04-30
SI3330293T1 (sl) 2019-10-30
AU2009313039B2 (en) 2015-06-18
RU2736802C2 (ru) 2020-11-20
HRP20150400T1 (hr) 2015-05-08
HUE036922T2 (hu) 2018-08-28
CN102209729A (zh) 2011-10-05
PT2918604T (pt) 2018-03-02
US20110262440A1 (en) 2011-10-27
PL2918604T3 (pl) 2018-05-30
EP2918604A1 (en) 2015-09-16
JP5798036B2 (ja) 2015-10-21
RS59348B1 (sr) 2019-10-31
SMT201500104B (it) 2015-07-09
ES2535257T3 (es) 2015-05-07
RU2014141180A3 (https=) 2018-06-09
EP3330293A1 (en) 2018-06-06
EP2344539A1 (en) 2011-07-20
HK1158667A1 (en) 2012-07-20
CN102209729B (zh) 2016-05-25
WO2010052013A1 (en) 2010-05-14
DK3330293T3 (da) 2019-10-07
RU2014141180A (ru) 2016-05-10
CN106390114A (zh) 2017-02-15
SG195549A1 (en) 2013-12-30
EP2344539B1 (en) 2015-02-11
RU2011122827A (ru) 2012-12-20

Similar Documents

Publication Publication Date Title
KR101695329B1 (ko) 소아 급성 림프구성 백혈병의 치료방법
KR101695327B1 (ko) 급성 림프구성 백혈병의 치료방법
HK1255590A1 (en) Treatment of pediatric acute lymphoblastic leukemia with bispecific antibodies against cd3xcd19
JP2022091793A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
EP4180449A1 (en) Chimeric receptors and methods of use thereof
CN118593691A (zh) 施用嵌合抗原受体免疫疗法的方法
CA2987716A1 (en) Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
HK40022438A (en) Treatment of pediatric acute lymphoblastic leukemia
HK1215258B (en) Treatment of pediatric acute lymphoblastic leukemia
HK1158667B (en) Treatment of pediatric acute lymphoblastic leukemia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20191217

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10